Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?"
- PMID: 34979133
- DOI: 10.1016/j.jhep.2021.12.025
Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?"
Conflict of interest statement
Conflicts of interest B.S. received travel support from AbbVie, Ipsen and Gilead. M.P. is an investigator for Bayer, BMS, Lilly, and Roche, he received speaker honoraria from Bayer, BMS, Eisai, and MSD, he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, Roche, and MSD, and he received travel support from Bayer, BMS, and Roche. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12. J Hepatol. 2022. PMID: 34648895
-
Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?J Hepatol. 2022 Apr;76(4):987-988. doi: 10.1016/j.jhep.2021.11.007. Epub 2021 Nov 13. J Hepatol. 2022. PMID: 34780876 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
